Sight Sciences, Inc. develops proprietary devices targeting interventional glaucoma and dry eye markets with flagship products including OMNI, SION, and TearCare. Since inception, the company has operated at a loss, driven by heavy investments in clinical trials, sales expansion, and regulatory initiatives. Revenue growth hinges on broader physician adoption and expanded reimbursement coverage, especially for TearCare. While operating losses narrowed in 2025 compared to prior years, cash flow remains negative, reflecting ongoing investment needs. Operational risks stem from concentrated third-party manufacturing and competitive market dynamics.